University of Hertfordshire

From the same journal

By the same authors

Standard

Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO) : Content Validity. / Goswami, Pushpendra; Oliva, Esther; Ionova, Tatyana; Else, R; Kell, J; Fielding, AK; Jennings, DM; Karakantza , M; Al-Ismail, S; Collins, GP; McConnell , S; Langton, Catherine; Salek, Sam.

In: Frontiers in Pharmacology, Vol. 11, 209, 05.03.2020, p. 209.

Research output: Contribution to journalArticlepeer-review

Harvard

Goswami, P, Oliva, E, Ionova, T, Else, R, Kell, J, Fielding, AK, Jennings, DM, Karakantza , M, Al-Ismail, S, Collins, GP, McConnell , S, Langton, C & Salek, S 2020, 'Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity', Frontiers in Pharmacology, vol. 11, 209, pp. 209. https://doi.org/10.3389/fphar.2020.00209

APA

Goswami, P., Oliva, E., Ionova, T., Else, R., Kell, J., Fielding, AK., Jennings, DM., Karakantza , M., Al-Ismail, S., Collins, GP., McConnell , S., Langton, C., & Salek, S. (2020). Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity. Frontiers in Pharmacology, 11, 209. [209]. https://doi.org/10.3389/fphar.2020.00209

Vancouver

Author

Goswami, Pushpendra ; Oliva, Esther ; Ionova, Tatyana ; Else, R ; Kell, J ; Fielding, AK ; Jennings, DM ; Karakantza , M ; Al-Ismail, S ; Collins, GP ; McConnell , S ; Langton, Catherine ; Salek, Sam. / Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO) : Content Validity. In: Frontiers in Pharmacology. 2020 ; Vol. 11. pp. 209.

Bibtex

@article{d8e1a6092a9b49d099a1d159c6941722,
title = "Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity",
abstract = "Background: The quality of life of patients at all stages of hematological malignancy is greatly affected by the disease and its treatment. There is a wide range of health-related quality of life (HRQoL) issues important to these patients. Any new instrument developed to measure HRQoL of such patients should be content valid, i.e., the items should be comprehensively relevant to the patients and their health condition. The aim of the present study was to examine content validity of a hematological malignancy specific patient reported outcome measure (HM-PRO) developed for use in routine clinical practice.Methods: Following literature review and semi-structured interviews, the generated themes and sub-themes were discussed to develop the prototype version of the HM-PRO. A 4-step approach was used for content validation: initial testing and cognitive interviewing; item rating; content validity panel meeting; final field testing and cognitive interviewing. Additional questions related to patients' perception of recall period and preferred sentence structure (i.e., question or statement) of the items were also asked during cognitive interviews.Results: The content analysis of 129 transcribed semi-structured interviews resulted in the prototype version of the instrument consisting of 58 items grouped into two parts: Part A (impact/HRQoL - 34 items) and Part B (signs and symptoms - 24 items). The initial testing showed intra-class correlation coefficient (ICC) of >0.8 for both Part A and Part B. Item rating for language clarity, completeness, relevance, and response scale by experts and patients showed content validity index for scales average >0.8 for both Part A and Part B, except 0.64 for relevance for Part A by the patient panel. The final testing of the revised version of the instrument showed the Cronbach's alpha value of 0.91 for Part A and 0.76 for Part B, suggesting high internal consistency, and ICC of 0.91 for Part A and 0.76 for Part B. The recall period of {"}today{"} for Part-A and {"}last 3 days{"} for Part-B were the patients' preferred {"}recall period.{"} Furthermore, the patients expressed preference to the HM-PRO items as statements.Conclusion: The findings of this study confirm that the HM-PRO possesses a strong content validity, includes all the issues important to patients and is easy to read, understand and respond to spontaneously.",
keywords = "HM-PRO, clinical practice, clinical research, content validity, hematological malignancy, quality of life, symptoms",
author = "Pushpendra Goswami and Esther Oliva and Tatyana Ionova and R Else and J Kell and AK Fielding and DM Jennings and M Karakantza and S Al-Ismail and GP Collins and S McConnell and Catherine Langton and Sam Salek",
note = "Copyright {\textcopyright} 2020 Goswami, Oliva, Ionova, Else, Kell, Fielding, Jennings, Karakantza, Al-Ismail, Collins, McConnell, Langton and Salek.",
year = "2020",
month = mar,
day = "5",
doi = "10.3389/fphar.2020.00209",
language = "English",
volume = "11",
pages = "209",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO)

T2 - Content Validity

AU - Goswami, Pushpendra

AU - Oliva, Esther

AU - Ionova, Tatyana

AU - Else, R

AU - Kell, J

AU - Fielding, AK

AU - Jennings, DM

AU - Karakantza , M

AU - Al-Ismail, S

AU - Collins, GP

AU - McConnell , S

AU - Langton, Catherine

AU - Salek, Sam

N1 - Copyright © 2020 Goswami, Oliva, Ionova, Else, Kell, Fielding, Jennings, Karakantza, Al-Ismail, Collins, McConnell, Langton and Salek.

PY - 2020/3/5

Y1 - 2020/3/5

N2 - Background: The quality of life of patients at all stages of hematological malignancy is greatly affected by the disease and its treatment. There is a wide range of health-related quality of life (HRQoL) issues important to these patients. Any new instrument developed to measure HRQoL of such patients should be content valid, i.e., the items should be comprehensively relevant to the patients and their health condition. The aim of the present study was to examine content validity of a hematological malignancy specific patient reported outcome measure (HM-PRO) developed for use in routine clinical practice.Methods: Following literature review and semi-structured interviews, the generated themes and sub-themes were discussed to develop the prototype version of the HM-PRO. A 4-step approach was used for content validation: initial testing and cognitive interviewing; item rating; content validity panel meeting; final field testing and cognitive interviewing. Additional questions related to patients' perception of recall period and preferred sentence structure (i.e., question or statement) of the items were also asked during cognitive interviews.Results: The content analysis of 129 transcribed semi-structured interviews resulted in the prototype version of the instrument consisting of 58 items grouped into two parts: Part A (impact/HRQoL - 34 items) and Part B (signs and symptoms - 24 items). The initial testing showed intra-class correlation coefficient (ICC) of >0.8 for both Part A and Part B. Item rating for language clarity, completeness, relevance, and response scale by experts and patients showed content validity index for scales average >0.8 for both Part A and Part B, except 0.64 for relevance for Part A by the patient panel. The final testing of the revised version of the instrument showed the Cronbach's alpha value of 0.91 for Part A and 0.76 for Part B, suggesting high internal consistency, and ICC of 0.91 for Part A and 0.76 for Part B. The recall period of "today" for Part-A and "last 3 days" for Part-B were the patients' preferred "recall period." Furthermore, the patients expressed preference to the HM-PRO items as statements.Conclusion: The findings of this study confirm that the HM-PRO possesses a strong content validity, includes all the issues important to patients and is easy to read, understand and respond to spontaneously.

AB - Background: The quality of life of patients at all stages of hematological malignancy is greatly affected by the disease and its treatment. There is a wide range of health-related quality of life (HRQoL) issues important to these patients. Any new instrument developed to measure HRQoL of such patients should be content valid, i.e., the items should be comprehensively relevant to the patients and their health condition. The aim of the present study was to examine content validity of a hematological malignancy specific patient reported outcome measure (HM-PRO) developed for use in routine clinical practice.Methods: Following literature review and semi-structured interviews, the generated themes and sub-themes were discussed to develop the prototype version of the HM-PRO. A 4-step approach was used for content validation: initial testing and cognitive interviewing; item rating; content validity panel meeting; final field testing and cognitive interviewing. Additional questions related to patients' perception of recall period and preferred sentence structure (i.e., question or statement) of the items were also asked during cognitive interviews.Results: The content analysis of 129 transcribed semi-structured interviews resulted in the prototype version of the instrument consisting of 58 items grouped into two parts: Part A (impact/HRQoL - 34 items) and Part B (signs and symptoms - 24 items). The initial testing showed intra-class correlation coefficient (ICC) of >0.8 for both Part A and Part B. Item rating for language clarity, completeness, relevance, and response scale by experts and patients showed content validity index for scales average >0.8 for both Part A and Part B, except 0.64 for relevance for Part A by the patient panel. The final testing of the revised version of the instrument showed the Cronbach's alpha value of 0.91 for Part A and 0.76 for Part B, suggesting high internal consistency, and ICC of 0.91 for Part A and 0.76 for Part B. The recall period of "today" for Part-A and "last 3 days" for Part-B were the patients' preferred "recall period." Furthermore, the patients expressed preference to the HM-PRO items as statements.Conclusion: The findings of this study confirm that the HM-PRO possesses a strong content validity, includes all the issues important to patients and is easy to read, understand and respond to spontaneously.

KW - HM-PRO

KW - clinical practice

KW - clinical research

KW - content validity

KW - hematological malignancy

KW - quality of life

KW - symptoms

UR - http://www.scopus.com/inward/record.url?scp=85082678241&partnerID=8YFLogxK

U2 - 10.3389/fphar.2020.00209

DO - 10.3389/fphar.2020.00209

M3 - Article

C2 - 32210809

VL - 11

SP - 209

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - 209

ER -